The popularity of Sildenafil initially drove a period of growth for pharma, but recent developments present a uncertain picture for shareholders. Off-patent competitors are reducing revenue, and persistent litigation https://anyattqt816058.wizzardsblog.com/41126548/viagra-and-the-pharmaceutical-industry-a-risky-investment